29.10.2012 - It is a significant upgrade for Italian basic research: British-Swiss Shire collaborates with Telethon Foundation on rare disease drugs.
It is a company first for British Shire Pharmaceuticals plc. Despite having had strong ties with academia for a while, the pharma firm has also finally partnered up in a public-private partnership (PPP) with an academic institution for the first time. Last week Swiss Shire Human Genetic Therapies – Shire’s stock corporation from Nyons – and Italian Telethon Foundation entered a long-term collaboration in discovering new medicines against rare diseases. In particular, Shire will spend over the next five years €17m on research on 13 mainly undisclosed indications. The only thing known is that a number of different lysosomal storage disorders and neurodegenerative disorders are among them. With this long-term collaboration, the British hope to boost their early stage pipeline. The terms for Shire picking up a ripening project and eventually bringing it through mid and late clinical stages are still under discussion.
Telethon general manager Francesca Pasinelli underscored the importance of the deal for her foundation: „For a not-for-profit organisation like ours, this alliance represents an opportunity to fulfil the promise made to patients and donors who have been supporting us.“ Most of the research will be carried out at the Telethon Institute of Genetics and Medicine (TIGEM) in Naples. The institute’s research strength lies in gene therapeutics.
Earlier this year Shire launched another early-stage programme together with zinc-finger-technology torchbearer Sangamo Bioscience (tackling haemophilia). While Shire now enters virgin soil with a public-private partnership, Telethon already has some experience in this respect. Since 2010 the foundation – together with GlaxoSmithKline – has been developing a gene therapy for the devastating immune deficiency ADA-SCID.
25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.
21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.
11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.
04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.
The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more